Touyun Biotech Group Ltd. has outlined its formal investment policy and portfolio strategy, emphasizing prudent and disciplined capital deployment to generate sustainable long-term returns and enhance shareholder value. The company’s future plans include maintaining a robust risk management framework, ensuring alignment with core business directions and financial obligations, and adhering to clear principles and guidelines for financial investments. The Board retains authority over major investment approvals, while management is tasked with continuous monitoring, due diligence, and execution of the strategy. The investment policy is subject to regular review to reflect changing market conditions, the Group’s financial position, and regulatory requirements. As of the end of 2024, the Group’s investment portfolio will remain focused on the financial services sector, including securities trading, brokerage, money lending, and asset management.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Touyun Biotech Group Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260130-12006594), on January 30, 2026, and is solely responsible for the information contained therein.